000739SZSE

Announcement on Obtaining Drug Registration Certificate

Apeloa Pharmaceutical Co., Ltd.··2 pages

✨ AI Summary

Zhejiang Pro-Health Pharmaceutical Co., Ltd. announces its subsidiary has received a Drug Registration Certificate for Cinnarizine Sustained-Release Tablets from the NMPA. This approval, classifying the drug as a Category 3 chemical drug, is deemed equivalent to a generic consistency evaluation. The product is expected to enrich the company's pipeline and enhance market competitiveness.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 000739

Securities Abbreviation: Pro-Health Pharma

Announcement No.: 2026-71

Pro-Health Pharmaceutical Co., Ltd.

Announcement on Obtaining Drug Registration Certificate

The Company and all members of the Board of Directors guarantee the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Recently, Zhejiang Pro-Health Pharmaceutical Co., Ltd. (hereinafter referred to as "Pro-Health Pharma"), a holding subsidiary of Pro-Health Pharmaceutical Co., Ltd. (hereinafter referred to as "Kangyu Pharma"), received a "Drug Registration Certificate" for Cinnarizine Sustained-Release Tablets issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). The relevant situation is hereby announced as follows:

I. Drug Registration Approval Status

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.